Shaanxi Kanghui Pharm Co Ltd (603139) - Net Assets
Based on the latest financial reports, Shaanxi Kanghui Pharm Co Ltd (603139) has net assets worth CN¥745.41 Million CNY (≈ $109.08 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.89 Billion ≈ $276.04 Million USD) and total liabilities (CN¥1.14 Billion ≈ $166.96 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 603139 financial resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥745.41 Million |
| % of Total Assets | 39.52% |
| Annual Growth Rate | 12.95% |
| 5-Year Change | -15.47% |
| 10-Year Change | 98.2% |
| Growth Volatility | 24.59 |
Shaanxi Kanghui Pharm Co Ltd - Net Assets Trend (2012–2024)
This chart illustrates how Shaanxi Kanghui Pharm Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore 603139 total asset value for the complete picture of this company's asset base.
Annual Net Assets for Shaanxi Kanghui Pharm Co Ltd (2012–2024)
The table below shows the annual net assets of Shaanxi Kanghui Pharm Co Ltd from 2012 to 2024. For live valuation and market cap data, see how much is Shaanxi Kanghui Pharm Co Ltd worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥906.90 Million ≈ $132.71 Million |
-11.08% |
| 2023-12-31 | CN¥1.02 Billion ≈ $149.25 Million |
-0.59% |
| 2022-12-31 | CN¥1.03 Billion ≈ $150.13 Million |
-7.99% |
| 2021-12-31 | CN¥1.12 Billion ≈ $163.16 Million |
+3.92% |
| 2020-12-31 | CN¥1.07 Billion ≈ $157.00 Million |
+5.52% |
| 2019-12-31 | CN¥1.02 Billion ≈ $148.79 Million |
+3.83% |
| 2018-12-31 | CN¥979.31 Million ≈ $143.30 Million |
+7.37% |
| 2017-12-31 | CN¥912.11 Million ≈ $133.47 Million |
+74.46% |
| 2016-12-31 | CN¥522.81 Million ≈ $76.50 Million |
+14.26% |
| 2015-12-31 | CN¥457.58 Million ≈ $66.96 Million |
+15.73% |
| 2014-12-31 | CN¥395.37 Million ≈ $57.86 Million |
+18.86% |
| 2013-12-31 | CN¥332.63 Million ≈ $48.67 Million |
+58.07% |
| 2012-12-31 | CN¥210.43 Million ≈ $30.79 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Shaanxi Kanghui Pharm Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 243.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥277.76 Million | 32.40% |
| Common Stock | CN¥99.88 Million | 11.65% |
| Other Comprehensive Income | CN¥69.21 Million | 8.07% |
| Other Components | CN¥410.48 Million | 47.88% |
| Total Equity | CN¥857.32 Million | 100.00% |
Shaanxi Kanghui Pharm Co Ltd Competitors by Market Cap
The table below lists competitors of Shaanxi Kanghui Pharm Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Yonker Environmental Protect
SHE:300187
|
$542.29 Million |
|
Lendingtree Inc
NASDAQ:TREE
|
$542.32 Million |
|
Chrysos Corporation Ltd
AU:C79
|
$542.34 Million |
|
Vinci Partners Investments Ltd
NASDAQ:VINP
|
$542.42 Million |
|
Hyundai Motor Securities Co. Ltd.
KO:001500
|
$542.23 Million |
|
Nextdoor Holdings Inc
NYSE:KIND
|
$542.17 Million |
|
MiMedx Group Inc
NASDAQ:MDXG
|
$542.05 Million |
|
Gokaldas Exports Limited
NSE:GOKEX
|
$542.05 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shaanxi Kanghui Pharm Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 949,233,877 to 857,322,192, a change of -91,911,685 (-9.7%).
- Net loss of 89,625,540 reduced equity.
- Dividend payments of 28,927,530 reduced retained earnings.
- Other comprehensive income decreased equity by 2,274,397.
- Other factors increased equity by 28,915,782.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-89.63 Million | -10.45% |
| Dividends Paid | CN¥28.93 Million | -3.37% |
| Other Comprehensive Income | CN¥-2.27 Million | -0.27% |
| Other Changes | CN¥28.92 Million | +3.37% |
| Total Change | CN¥- | -9.68% |
Book Value vs Market Value Analysis
This analysis compares Shaanxi Kanghui Pharm Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.31x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 11.68x to 4.31x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | CN¥3.18 | CN¥37.10 | x |
| 2013-12-31 | CN¥4.59 | CN¥37.10 | x |
| 2014-12-31 | CN¥5.29 | CN¥37.10 | x |
| 2015-12-31 | CN¥6.11 | CN¥37.10 | x |
| 2016-12-31 | CN¥6.97 | CN¥37.10 | x |
| 2017-12-31 | CN¥9.97 | CN¥37.10 | x |
| 2018-12-31 | CN¥9.53 | CN¥37.10 | x |
| 2019-12-31 | CN¥9.79 | CN¥37.10 | x |
| 2020-12-31 | CN¥10.09 | CN¥37.10 | x |
| 2021-12-31 | CN¥10.48 | CN¥37.10 | x |
| 2022-12-31 | CN¥9.75 | CN¥37.10 | x |
| 2023-12-31 | CN¥9.43 | CN¥37.10 | x |
| 2024-12-31 | CN¥8.61 | CN¥37.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shaanxi Kanghui Pharm Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -10.45%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -15.96%
- • Asset Turnover: 0.30x
- • Equity Multiplier: 2.20x
- Recent ROE (-10.45%) is below the historical average (6.22%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 19.20% | 14.59% | 0.88x | 1.50x | CN¥19.36 Million |
| 2013 | 16.78% | 17.02% | 0.73x | 1.35x | CN¥22.56 Million |
| 2014 | 15.87% | 16.70% | 0.74x | 1.28x | CN¥23.20 Million |
| 2015 | 13.59% | 16.38% | 0.66x | 1.26x | CN¥16.45 Million |
| 2016 | 12.48% | 17.08% | 0.58x | 1.25x | CN¥12.95 Million |
| 2017 | 6.92% | 17.17% | 0.36x | 1.13x | CN¥-28.06 Million |
| 2018 | 5.88% | 14.81% | 0.34x | 1.17x | CN¥-39.02 Million |
| 2019 | 4.37% | 9.91% | 0.38x | 1.16x | CN¥-55.06 Million |
| 2020 | 3.39% | 8.24% | 0.32x | 1.30x | CN¥-66.66 Million |
| 2021 | 3.49% | 8.24% | 0.24x | 1.78x | CN¥-68.19 Million |
| 2022 | -7.89% | -15.62% | 0.27x | 1.87x | CN¥-174.16 Million |
| 2023 | -2.76% | -3.89% | 0.33x | 2.16x | CN¥-121.08 Million |
| 2024 | -10.45% | -15.96% | 0.30x | 2.20x | CN¥-175.36 Million |
Industry Comparison
This section compares Shaanxi Kanghui Pharm Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $4,691,234,838
- Average return on equity (ROE) among peers: 6.16%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shaanxi Kanghui Pharm Co Ltd (603139) | CN¥745.41 Million | 19.20% | 1.53x | $542.24 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $903.62 Million | 4.28% | 2.45x | $1.16 Billion |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.22 Billion | 5.35% | 1.27x | $441.99 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $9.87 Billion | 20.71% | 0.25x | $5.01 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $1.07 Billion | 3.83% | 0.46x | $2.80 Billion |
| Wedge Industrial Co Ltd (000534) | $1.15 Billion | 11.42% | 1.59x | $3.04 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $9.03 Billion | 25.71% | 0.43x | $13.75 Billion |
| Hainan Haiyao Co Ltd (000566) | $275.57 Million | 17.28% | 1.12x | $947.33 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $231.22 Million | -38.13% | 1.23x | $389.67 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $4.29 Billion | 2.31% | 2.07x | $1.03 Billion |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $18.87 Billion | 8.83% | 0.08x | $3.32 Billion |
About Shaanxi Kanghui Pharm Co Ltd
Shaanxi Kanghui Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China. It offers gynecological, orthopedic, dermatology, diabetes, respiratory system, urinary system, cardiovascular, tranquilizer, gastrointestinal, hepatobiliary, and other drugs in the form of tablets, capsules, granules, mixtures, teas, plasters, ointments, lin… Read more